Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment-Reference-Cited by-同舟云学术

Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment

Published:2011-12 Issue:1 Volume:12 Page:
ISSN:1465-993X
Container-title:Respiratory Research
language:en
Short-container-title:Respir Res

Author:

Azuma Arata, ,Taguchi Yoshio,Ogura Takashi,Ebina Masahito,Taniguchi Hiroyuki,Kondoh Yasuhiro,Suga Moritaka,Takahashi Hiroki,Nakata Koichiro,Sato Atsuhiko,Kudoh Shoji,Nukiwa Toshihiro

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/1465-9921-12-143.pdf

Reference25 articles.

1. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP: Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998, 157: 199-203.

2. Schwartz DA, Helmers RA, Galvin JR, Van Fossen DS, Frees KL, Dayton CS, Burmeister LF, Hunninghake GW: Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1994, 149: 450-454.

3. Azuma A: Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis. Expert Rev Resp Med. 2010, 4: 301-310. 10.1586/ers.10.32.

4. Raghu G, Johnson WC, Lockhart D, Mageto Y: Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med. 1999, 159: 1061-1069.

5. Gahl WA, Brantly M, Troendle J, Avila NA, Padua A, Montalvo C, Cardona H, Calis KA, Gochuico B: Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab. 2002, 76: 234-242. 10.1016/S1096-7192(02)00044-6.

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What causes cough in pulmonary fibrosis, and how should we treat it?;Current Opinion in Pulmonary Medicine;2024-06-24

2. Osteoprotegerin is an Early Marker of the Fibrotic Process and of Antifibrotic Treatment Responses in Ex Vivo Lung Fibrosis;Lung;2024-04-20

3. Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases;Heliyon;2024-04

4. Patients with idiopathic pulmonary fibrosis and refractory cough have traction bronchiectasis and distorted airway architecture: a retrospective case review study;Journal of Thoracic Disease;2024-03

5. Pirfenidone alleviates chronic pancreatitis via suppressing the activation of pancreatic stellate cells and the M1 polarization of macrophages;International Immunopharmacology;2024-03